6 ADVERSE REACTIONS ADVERSE REACTIONS SECTION The following serious adverse reactions are described below or elsewhere in the prescribing information: Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)] Acute Pancreatitis [see Warnings and Precautions (5.2)] Acute Gallbladder Disease [see Warnings and Precautions (5.3)] Hypoglycemia [see Warnings and Precautions (5.4)] Acute Kidney Injury Due to Volume Depletion [see Warnings and Precautions (5.5)] Severe Gastrointestinal Adverse Reactions [see Warnings and Precautions (5.6)] Hypersensitivity Reactions [see Warnings and Precautions (5.7)] Diabetic Retinopathy Complications in Patients with Type 2 Diabetes [see Warnings and Precautions (5.8)] Heart Rate Increase [see Warnings and Precautions (5.9)] Pulmonary Aspiration During General Anesthesia or Deep Sedation [see Warnings and Precautions ( 5.10 )] 6.1 Clinical Trials Experience SPL UNCLASSIFIED SECTION Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice

are both acceptable things to ask
Another investigation involving 7.5 grams of allulose administered before a meal showed trends toward elevated GLP-1 concentrations, but these findings did not consistently reach statistical significance across all measured time points
While the standard four-week titration provides a useful framework, your individual experienceyour rate of weight loss, your food noise, and your side effect toleranceis the most important factor
Always follow the instructions for use provided by Eli Lilly and Company
Journal Haematology 111 (2), 407415